North American Prodromal Synucleinopathy (NAPS) Consortium


About this study

The purpose of this study is to establish a registry of RBD patients, develop quantitative biological and functional measures of synucleinopathy burden, and establish a formal process to evaluate candidate neuroprotective agents.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Undergone an overnight polysomnogram that was used to diagnose REM Sleep Behavior Disorder.
  • 18 years of age or older.
  • Capable of providing informed consent using the current IRB approved consent document.

Exclusion Criteria:

  • Known diagnosis of PD, dementia of any type, or MSA,
  • RBD associated with narcolepsy or suspected due to another neurological etiology (i.e. non-idiopathic RBD),
  • For Lumbar puncture only: Anticoagulant medication or bleeding disorder,
  • For Lumbar puncture only: Prior lumbar surgery or procedure that precludes LP.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Bradley Boeve, M.D.

Closed-enrolling by invitation

What is this? (?)
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Alzheimer’s Disease Research Center

(507) 284-1324

More information


Publications are currently not available

Mayo Clinic Footer